INIT — Initiator Pharma A/S Share News
0.000.00%
Last trade - 00:00- SEK195.09m
- SEK176.92m
Brief: Initiator Reports Positive Phase IIb Efficacy Data With Pudafensine
Brief: Initiator Pharma Q2 Operating Loss Narrows To At DKK 8.9 Mln
Brief: Initiator Pharma Obtains Patent In Europe
Brief: Initiator Pharma - Positive Results From Pudafensine Phase I Pharmacokinetic Trial
Brief: Finalization Of Share Buyback Program In Initiator Pharma
Brief: Initiator Pharma Reports Dose-Dependent Significant Efficacy Of Ip2018
Brief: Initiator Pharma Q1 Operating Loss DKK 8.7 Million
Brief: Initiator Pharma Q4 EBIT Loss Narrows To DKK 6.5 Mln
Brief: Initiator Pharma Decides Not To Exercise Option For Pain Asset
Brief: Initiator Pharma To Start Phase I Pharmacokinetics Study For New Ip2015 Formulations
Brief: Initiator Pharma Q3 EBIT Loss Narrows To DKK 6.7 Mln
Brief: Initiator Pharma Reports Final Analysis Of Positive Efficacy Data From IPTN2021 Program Phase I Study
Brief: Initiator Pharma Q2 EBIT Loss DKK 13.5 Mln
Brief: Initiator Pharma Completes Share Buyback Program
Brief: Initiator Pharma To Prolong Share Buyback Program
Brief: Initiator Pharma Announces Outcome Of Rights Issue
Brief: Board Of Directors Decides On Execution Of Rights Issue
Brief: Initiator Pharma Q1 Operating Loss Widens To DKK 15.1 Mln
Brief: Initiator Pharma: Board Proposes Directed Share Issue, Fully Guaranteed Rights Issue Of SEK 61 Mln